Wells Fargo
EVFM

Wells Fargo’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Wells Fargo’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-342
Closed – – 7941
2022
Q2 		$0 Buy
342
+59
+21% +$97 ﹤0.01% 8009
2022
Q1 		$1K Sell
283
-1
-0.4% -$6 ﹤0.01% 6942
2021
Q4 		$1K Buy
284
+3
+1% +$26 ﹤0.01% 7141
2021
Q3 		$3K Sell
281
-2
-0.7% -$25 ﹤0.01% 6538
2021
Q2 		$4K Sell
283
-1,451
-84% -$27.5K ﹤0.01% 6434
2021
Q1 		$45K Sell
1,734
-1,897
-52% -$86.2K ﹤0.01% 5864
2020
Q4 		$132K Buy
3,631
+1,248
+52% +$45.1K ﹤0.01% 5250
2020
Q3 		$85K Sell
2,383
-402
-14% -$17.5K ﹤0.01% 5325
2020
Q2 		$118K Buy
2,785
+1,359
+95% +$91.6K ﹤0.01% 5147
2020
Q1 		$114K Sell
1,426
-43
-3% -$3.44K ﹤0.01% 4996
2019
Q4 		$136K Buy
1,469
+1
+0.1% +$84 ﹤0.01% 5164
2019
Q3 		$111K Buy
1,468
+1,461
+20,871% +$112K ﹤0.01% 5272
2019
Q2 		$1K Buy
+7
New +$542 ﹤0.01% 6316
2016
Q2 		– Sell
-9
Closed – – 6431
2016
Q1 		$0 Sell
9
-13
-59% -$1K ﹤0.01% 6530
2015
Q4 		$3K Hold
22
– – ﹤0.01% 5986
2015
Q3 		$16K Buy
22
+20
+1,000% +$21.5K ﹤0.01% 5611
2015
Q2 		$2K Buy
+2
New +$1.28K ﹤0.01% 6184

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Wells Fargo's EVFM Position: Q3 2022 in Review

Wells Fargo sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 342 shares.

Wells Fargo first reported a position in EVFM in Q2 2015 and held it in 17 quarters. The position peaked at $136K in Q4 2019. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • Wells Fargo reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Wells Fargo sold 342 Evofem Biosciences, Inc. Common Stock shares in Q3 2022.
  • Wells Fargo first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2015 and held it in 17 quarters.
  • Wells Fargo's Evofem Biosciences, Inc. Common Stock position peaked at $136K in Q4 2019.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on Wells Fargo's 13F filing for Q3 2022, filed 14 Nov 2022.